Short Interest in Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Rises By 217.2%

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 20,300 shares, a growth of 217.2% from the March 15th total of 6,400 shares. Based on an average daily trading volume, of 52,600 shares, the short-interest ratio is presently 0.4 days. Currently, 0.0% of the shares of the stock are short sold.

Enzon Pharmaceuticals Stock Down 3.7 %

ENZN traded down $0.00 during trading on Wednesday, reaching $0.09. The company’s stock had a trading volume of 4,228 shares, compared to its average volume of 71,203. The company has a market cap of $7.02 million, a price-to-earnings ratio of 9.47 and a beta of 0.23. The firm has a fifty day simple moving average of $0.11 and a two-hundred day simple moving average of $0.12. Enzon Pharmaceuticals has a 1 year low of $0.06 and a 1 year high of $0.24.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.